Eli Lilly completes purchase of Centessa Pharmaceuticals, adding orexin-2 agonist pipeline for sleep-wake disorders

Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals plc, moving the UK clinical-stage developer into the Lilly portfolio as it works to expand treatment options for sleep-wake disorders. Lilly said the deal closes successfully, positioning Centessa’s investigational approach around orexin receptor 2, a target associated with regulating arousal and sleep-related processes.

Centessa is described in the announcement as a clinical-stage company, and Lilly’s stated rationale centers on a new class of potential therapies: orexin receptor 2 agonists. By aiming to activate orexin receptor 2, these drug candidates are designed to influence the body’s sleep-wake control systems, an area where approved options can be limited and where patient needs remain broad.

The announcement ties the acquisition to Lilly’s broader neuroscience strategy, framing Centessa’s program as a contribution to a pipeline intended to advance treatments across conditions that affect brain function and behavior. Sleep-wake disorders, while diverse, are often characterized by disrupted timing or regulation of sleep and wakefulness, making the underlying biology an active focus for drug development.

Lilly did not provide, in the posted coverage, specific commercial terms such as the purchase price, milestones, or ongoing development commitments. It also did not disclose in the cited post any detailed regulatory status for Centessa’s orexin receptor 2 agonist program, such as which studies are ongoing, what endpoints are being tracked, or the timing of any future readouts.

Orexin receptor agonism has drawn industry attention because orexin indicating is linked to wakefulness and the stability of sleep. In that context, orexin receptor 2 agonists represent a targeted way to modify sleep-wake dynamics, rather than relying solely on drugs that primarily promote sedation or adjust neurotransmitter activity more broadly. Lilly’s decision to fold a clinical-stage effort into its organization suggests it sees value in adding this mechanism to its innovation pipeline.

The acquisition also reflects a wider pattern in the pharmaceutical sector, where large companies continue to buy clinical-stage assets to fill pipeline gaps and refresh their therapeutic breadth. In sleep-related indications, competitive development has intensified as companies seek to translate mechanistic biology into safe, effective medicines with distinct dosing profiles and patient-relevant outcomes.

For now, the practical implications for investors and patients hinge on what Centessa’s orexin receptor 2 agonist program can demonstrate as clinical data accumulate. What remains unclear from the announcement coverage is which specific compounds are included, their lead candidates’ clinical stage, and how Lilly expects to sequence development across indications or geographies.

Going forward, market watchers will likely focus on whether Lilly updates the program’s development timeline after the close, and whether it provides additional detail on clinical trial design, next clinical milestones, and regulatory plans for orexin receptor 2 agonists. Additional disclosures, including any integration steps for trial operations and future study locations, could shape expectations for the pace of advancement.